 Connection
Claudia Clavijo to Sirolimus
This is a "connection" page, showing publications Claudia Clavijo has written about Sirolimus.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.483 |
|
|
|
-
Clavijo C, Strom T, Moll V, Betts R, Zhang YL, Christians U, Bendrick-Peart J. Development and validation of a semi-automated assay for the highly sensitive quantification of Biolimus A9 in human whole blood using high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Nov 01; 877(29):3506-14.
Score: 0.271
-
Tada N, Virmani R, Grant G, Bartlett L, Black A, Clavijo C, Christians U, Betts R, Savage D, Su SH, Shulze J, Kar S. Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model. Circ Cardiovasc Interv. 2010 Apr; 3(2):174-83.
Score: 0.071
-
Steudel W, Dingmann C, Zhang YL, Bendrick-Peart J, Clavijo C, Shulze J, Betts R, Christians U. Randomized, double-blind, placebo-controlled, single intravenous dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of the novel coronary smooth muscle cell proliferation inhibitor Biolimus A9 in healthy individuals. J Clin Pharmacol. 2011 Jan; 51(1):29-39.
Score: 0.071
-
Christians U, Klawitter J, Clavijo CF. Bioequivalence testing of immunosuppressants: concepts and misconceptions. Kidney Int Suppl. 2010 Mar; (115):S1-7.
Score: 0.070
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|